UNSPSC 51101678: Ponazuril

This classification denotes an antiprotozoal agent with the molecular formula C18H14F3N3O6S, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier JPW84AS66U, chemically known as 1-methyl-3-(4-(p-((trifluoromethyl)sulfonyl)phenoxy)-m-tolyl)-s-triazine-2,4,6(1h,3h,5h)-trione. but generally known as ponazuril, which bears US NIH Compound Identifier 3050408. The term PONAZURIL is an International Non-Proprietary Name or INN (see WHO INN reference publication, Volume 13 No. 3, 1999, List 42).

Most nations schedule ponazuril under HS 29336980 and SITC 51576. As of Q4 2014, PONAZURIL remains the US FDA Preferred Term for this commodity. Ponazuril bears US NLM identifiers UMLS ID C0961649 and NCI Concept Code C72600. SMILES: CC1=C(C=CC(=C1)N2C(=O)NC(=O)N(C2=O)C)OC3=CC=C(C=C3)S(=O)(=O)C(F)(F)F.

UNSPSC 51101678 Ponazuril is a Commodity code that nominally refers to a specific antiprotozoal pharmaceutical, yet recent state and local opportunities tagged under this code show a disconnect—the code is being applied to broader pharmaceutical procurement including naloxone, generic multi-source drugs, over-the-counter products, and medical supply contracting rather than ponazuril specifically. State and local governments are using this code designation in mixed ways: county health departments procure emergency response pharmaceuticals and drug deactivation systems; state health and human services commissions solicit direct-to-manufacturer prescription fulfillment capabilities; city fire departments seek medical and first aid supplies; and regional cooperative purchasing alliances issue RFPs for generic pharmaceuticals and OTC products to be distributed across member facilities. The issuing bodies span county health departments, state agencies, municipal fire and purchasing departments, and multistate cooperative purchasing consortia. Work scopes range from emergency response supplies (naloxone, cardiac monitoring equipment, airway devices) to routine pharmaceutical supply chain management under various pricing and distribution models (wholesaler-mediated, direct-to-manufacturer, cooperative purchasing).

Recent activity appears concentrated in the Southeast and Upper Midwest. Seminole County, Florida issued IFB 60459723LAS in June 2026 seeking 1,900 units of naloxone and 800 safe drug deactivation systems annually with quarterly deliveries and a two-year initial term plus one-year renewal option. The Texas Health and Human Services Commission posted RFI HHS0017013 in April 2026 to gather vendor capabilities for direct-to-manufacturer prescription programs outside traditional pharmacy benefit manager arrangements. The City of Tampa's Purchasing Department released IFB 26P00145 in March 2026 for 169 line items of medical and first aid supplies for the Tampa Fire Department Rescue Division, estimated at $700,000.00, with a one-year award term and two optional one-year renewals, designated as a sheltered market for certified Small Local Business Enterprises with a 5 percent bid discount up to $10,000. The Minnesota Multistate Cooperative Purchasing Alliance (MMCAP), administered by the Minnesota Department of Administration, issued RFP S1070000015802 in January 2026 for generic multi-source pharmaceuticals and OTC products, due March 26, 2026, with products distributed through AmerisourceBergen (Cencora), Cardinal Health, and Morris & Dickson, contract effective July 1, 2026 for two years.